Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

NCT07052604 — Recruiting, 300 participants, Centre Hospitalier de Saint-Denis

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT07052604
Status	Recruiting
Study type	Observational
Enrollment	300 (Estimated)
Sponsor	Centre Hospitalier de Saint-Denis (Other)
Conditions	Pneumonia, Ventilator-Associated, Stenotrophomonas Maltophilia, Intensive Care Units, Anti-Bacterial Agents, Drug Resistance, Bacterial
Dates	start 2023-12-15, primary completion 2025-09-15 (estimated), completion 2025-09-15 (estimated), first posted 2025-07-04, last updated 2025-07-04
Locations	1 site in France

-Summary

This study looks at how different antibiotic treatments affect patients in intensive care who have pneumonia caused by the bacteria Stenotrophomonas maltophilia. It compares using one antibiotic versus two antibiotics, and treatment lengths of 7 days versus 14 days, to see which approach helps patients survive better. The study also examines how resistant the bacteria are to antibiotics and how often the pneumonia comes back.

Expand all sections · Collapse all

+Outcome measures

Primary outcomes

patient survival based on the antibiotic treatment strategy used (monotherapy vs. combination therapy and 7 vs. 14 days duration). [28 days]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Adult patients (age ≥ 18 years)
* Hospitalized in Medical Intensive Care Unit between January 1, 2018, and December 31, 2023
* Intubated and mechanically ventilated
* Diagnosed with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia

Exclusion Criteria:

* Patients under 18 years old
* Patients who refuse the use of their data for research purposes

+Locations (1)

Facility	City	Country	Status
Centre Hospitalier de Saint-Denis	Saint-Denis, France	France	Recruiting